Context Therapeutics (CNTX) Treasury Shares (2020 - 2021)

Context Therapeutics' (CNTX) quarterly Treasury Shares came in at $33398.0 in Q3 2021, up 74117.78% quarter-over-quarter from $45.0 in Q4 2020.

Context Therapeutics (CNTX) Treasury Shares (2020 - 2021) Analysis & Trends

Context Therapeutics has disclosed Treasury Shares across 2 years of filings, most recently posting $33398.0 for Q3 2021.

Treasury Shares for Q3 2021 came in at $33398.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2021 was $33398.0 (changed N/A YoY), and the FY2020 annual result was $45.0, changed N/A from the prior year.
Treasury Shares came in at $33398.0 for Q3 2021 at Context Therapeutics, up from $45.0 in the prior quarter.
In the past five years, Treasury Shares ranged from a high of $33398.0 in Q3 2021 to a low of $45.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-	-
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-	-
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-	1.48 Mn
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn	700,000.00
9	Abivax	94.26 Bn	94.26 Bn	-	-
10	Context Therapeutics	166.57 Mn	166.57 Mn	-	-

Download Data